Abstract: The present invention pertains to a dendritic cell-based vaccine against rh-?-Syn, ?-synuclein specific peptide antibodies and related vaccines, and methods of treating, preventing, and/or vaccinating against Parkinson's Disease (PD), or symptoms thereof.

Abstract: Embodiments of the present disclosure provide for ?-AApeptides, ?-AApeptide building blocks, methods of making ?-AApeptides and libraries of ?-AApeptides, methods of screening the ?-AApeptide libraries for desired peptidomimetic activity, and the like. The present disclosure also provides for ?-AApeptides that are inhibitors of A? peptide aggregation, methods of inhibiting and disassembling A? peptide aggregation, methods of inhibiting the toxicity of A? aggregates towards N2a neuroblasotma cells, as well as methods and compounds for treating Alzheimer's disease.

Abstract: Embodiments of the present disclosure provide for ?-AApeptides, ?-AApeptide building blocks, methods of making ?-AApeptides and libraries of ?-AApeptides, methods of screening the ?-AApeptide libraries for desired peptidomimetic activity, and the like. The present disclosure also provides for ?-AApeptides that are inhibitors of A? peptide aggregation, methods of inhibiting and disassembling A? peptide aggregation, methods of inhibiting the toxicity of A? aggregates towards N2a neuroblasotma cells, as well as methods and compounds for treating Alzheimer's disease.

Abstract: A method of treating and preventing a neurological disorder, such as Alzheimer's disease, in a subject in need thereof by positioning an electromagnetic field emitting source proximal to the subject and exposing the subject to an electromagnetic field having a predetermined frequency (preferably ?300-3,000 MHz) for a predetermined absorption period (preferably greater than ?3 days). Each individual treatment (comprising exposure to the predetermined frequency for the predetermined absorption period) is continued at a predetermined schedule for a predetermined treatment period. The EMF can have a specific absorption rate up to about 8 W/kg. The methodology enhances cognition in the subject and/or treats/prevents the underlying neurological disorder or a symptom thereof.

Abstract: The invention includes a method of treating and preventing a neurological disorder, such as Alzheimer's Disease, in a subject in need thereof by positioning an electromagnetic field emitting source proximal to the subject and exposing the subject to an electromagnetic field having a predetermined frequency for a predetermined absorption period. Preferably, each individual treatment (comprising exposure to the predetermined frequency for the predetermined absorption period) is continued at a predetermined schedule (preferably daily) for a predetermined treatment period. The predetermined frequency, according to a preferred embodiment, is about 918 MHz with a specific absorption rate (SAR) of about 0.25 W/kg+/?2 dB. The predetermined absorption period of this preferred embodiment is about one hour. The treatment period is long-term, being greater than about 6 months and preferably between about 7 and 9 months.

Abstract: The present invention relates to the field of polymer chemistry and more particularly to encapsulated peptides and uses thereof.

Abstract: Changes in adaptive immune system were identified and correlated as a predictor of A?40 and A?42 and AD progression. T-cell, B-cell, TCR and BCR profiles were used to correlate clinical progression of AD. The CDR3 region was spectratyped, showing the clonality of the CDR3 region. This intrafamily gene fragment length profile was compared to age-matched controls, thereby indicating the existence of a neurodegenerative disease. The novel method is useful in diagnosing neurodegenerative disease, like Parkinson's disease, HIV-associated Dementia, or Alzheimer's disease. Moreover, this permits the clinical identification of patients at a very early stage of AD and/or monitoring the potential benefits of disease modifying therapeutics.

Abstract: The application describes several mutant amyloid beta peptides and specific regions which are useful in the therapeutic and diagnostic of neurological diseases. The application further describes methods of using these mutant peptides as treatment and reagents for diagnosis of diseases. The application further describes diagnostic kits and pharmaceutical compositions for use in therapy to treat neurological diseases including but not limited to Alzheimer's disease and various forms of mild cognitive impairments.

Abstract: The invention includes a method of treating and preventing a neurological disorder, such as Alzheimer's Disease, in a subject in need thereof by positioning an electromagnetic field emitting source proximal to the subject and exposing the subject to an electromagnetic field having a predetermined frequency for a predetermined absorption period. Preferably, each individual treatment (comprising exposure to the predetermined frequency for the predetermined absorption period) is continued at a predetermined schedule (preferably daily) for a predetermined treatment period. The predetermined frequency, according to a preferred embodiment, is about 918 MHz with a specific absorption rate (SAR) of about 0.25 W/kg+/?2 dB. The predetermined absorption period of this preferred embodiment is about one hour. The treatment period is long-term, being greater than about 6 months and preferably between about 7 and 9 months.

Abstract: A method of treating HIV infection by using the novel anti-HIV activity of the opioid antagonist naloxone.

Abstract: The application describes several mutant amyloid beta peptides and specific regions which are useful in the therapeutic and diagnostic of neurological diseases. The application further describes methods of using these mutant peptides as treatment and reagents for diagnosis of diseases. The application further describes diagnostic kits and pharmaceutical compositions for use in therapy to treat neurological diseases including but not limited to Alzheimer's disease and various forms of mild cognitive impairments.

Abstract: The present invention relates to the field of polymer chemistry and more particularly to encapsulated peptides and uses thereof.

Abstract: The present invention is a method of effectively dissociating an antibody and antigen from the complex they form. The method enables researchers to accurately identify anti-amyloid beta peptide and its antibody from sera samples. It can also be used for the evaluation of the outcome of Alzheimer's patient treatment based on the amyloid peptide load and antibody level in the sera.